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Abstract
Background: Diabetes mellitus places a considerable burden on patients in terms of morbidity and mortality and
on society in terms of costs. Costs related to diabetes are expected to increase due to increasing prevalence of
type 2 diabetes. The aim of this study was to estimate the health care costs attributable to type 1 and type 2
diabetes in Norway in 2005.
Methods: Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, medical equipment,
nutrition guidance, physiotherapy, acupuncture, foot therapy and indirect costs were collected from national
registers and responses to a survey of 584 patients with diabetes. The study was performed with a prevalence
approach. Uncertainty was explored by means of bootstrapping.
Results: When hospital stays with diabetes as a secondary diagnosis were excluded, the total costs were €293
million, which represents about 1.4% of the total health care expenditure. Pharmaceuticals accounted for €95
million (32%), disability pensions €48 million (16%), medical devices €40 million (14%) and hospital admissions €21
million (7%). Patient expenditures for acupuncture, physiotherapy and foot therapy were many times higher than
expenditure for nutritional guidance. Indirect costs (lost production from job absenteeism) accounted for €70.1
million (24% of the €293 million) and included sick leave (€16.7 million), disability support and disability pensions
(€48.2 million) and other indirect costs (€5.3 million). If all diabetes related hospital stays are included (primary- and
secondary diagnosis) total costs amounts to €535 million, about 2.6% of the total health care expenditure in
Norway.
Conclusions: Diabetes represents a considerable burden to society in terms of health care costs and productivity
losses.
Background
Diabetes mellitus places a considerable burden on
patients in terms of morbidity [1] and mortality [2] and
on society in terms of costs [3-5]. The prevalence of
t y p e2d i a b e t e si si n c r e a s i n gi nm a n yc o u n t r i e s[ 6 ]
including Norway [7]. The number of patients with type
1 diabetes has been estimated at 25,000 [8]. In 2005,
117,600 persons in Norway were treated with insulin or
oral antidiabetics [9]. We then assume that 92,600 of
them have type 2 diabetes. In the Norwegian HUNT
study [10] the proportion of patients with type 2 dia-
b e t e st h a tw a sn o to na n t i d i a betic pharmaceuticals was
30%. This would imply that the total number of patients
with type 2 diabetes is 132,300 (92,600/0.7) [8-11].
Additionally, a large number of persons with type 2
diabetes are assumed to be undiagnosed. It has been
estimated that about 3-4% of the population above the
age of 30 have type 2 diabetes [8].
Cost-of-illness analysis is a type of study that has been
designed to quantify and value all economic conse-
quences of a disease without taking into account the
benefits of treatment. Therefore, cost-of-illness analysis
i ni t s e l fm a yn o tg u i d ep r i o r i t ys e t t i n g ,b u tm a yb eu s e -
ful in designing financing systems and setting priorities
for research.
There are two main approaches to cost-of-illness ana-
l y s i s :t h ep r e v a l e n c e[ 3 , 1 2 - 1 5 ]a n dt h ei n c i d e n c e[ 1 6 ]
approach. The former accounts for all prevention, treat-
ment and rehabilitation costs incurred during a given
year, while the latter measures all such costs for new
cases of the disease in a given year (the index year).
Future treatment costs are accounted for by estimating
the future costs for all individuals who develop the dis-
ease in the index year, and the present value of the
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The prevalence approach has the advantage of relating
to measures of total annual health care expenditure, and
it may yield more accurate estimates because it is based,
at least in principle, on observed costs rather than pro-
jected ones. The advantage of the incidence approach
lies in the fact that it provides projections of future
costs that may be very different from current ones when
incidence is increasing or declining. Such projections,
however, may be uncertain.
The aim of this study was to quantify, using the preva-
lence approach, the societal costs in Norway of type 1
and type 2 diabetes, including indirect costs (productiv-
ity losses from diabetes).
Methods
The study was based on register data for the entire Nor-
wegian population (n = 4.6 million). In addition we per-
f o r m e das u r v e yo f5 8 4p e r s o n sw i t hd i a b e t e s .W e
aimed at including all diabetes related costs, but some
data were unavailable (e.g. depression, erectile dysfunc-
tion, neuropathic pain, osteoarthritis, congestive heart
failure and pulmonary disease).
Direct costs
Direct costs are the costs of detection, treatment, pre-
vention, rehabilitation and long-term care arising from
an illness. In theory, all relevant health care and non-
health care costs are included, but in practice there is a
l i m i tt ow h a tc a nb ei d e n t i f i e da n dm e a s u r e d .D a t a
were, as far as possible, captured for 2005 and expressed
in 2005 EURO (1 € ≈ 8.50 Norwegian Kroner).
Inpatient hospital services
From the Norwegian Patient Register (NPR) we
obtained information on all hospital stays with the fol-
lowing ICD-10 codes as main or secondary diagnosis:
E10 (insulin-dependent diabetes mellitus), E11 (non-
insulin-dependent diabetes mellitus), E23.2 (diabetes
insipidus), H28.0 (diabetic cataract), N08.3 (glomerular
disorders in diabetes mellitus), O24 (diabetes mellitus in
pregnancy), P70.0 (syndrome of infant of mother with
gestational diabetes), P70.1 (syndrome of infant of a dia-
betic mother), P70.2 (neonatal diabetes mellitus), R73.0
(abnormal glucose tolerance test) and Z13.1 (special
screening examination for diabetes mellitus). For each
stay we obtained anonymous data on the primary diag-
nosis, secondary diagnosis, age, gender, geographic loca-
tion, length of stay and DRG-weight. In Norway,
patients receive a main diagnosis and possibly one or
more secondary diagnoses at discharge from hospital.
ICD10 has been used since 1999. On the basis of the
diagnoses, age, sex and possibly procedures, patients are
allocated to a diagnosis related group (DRG). The
Directorate of Health performs annual cost studies of a
representative sample of hospitals in order to estimate
the mean hospital costs of patients in each DRG. Even
though the cost estimate may be incorrect for the indi-
vidual patient, on average they represent reasonable
costs for the different types of patients. Hospital services
are provided by five Regional Health Authorities, each
with an independent board. Regional variation was ana-
lysed according to these units.
Outpatient clinic visits
Using the same ICD-10 codes as for inpatient services,
data on the costs of outpatient clinic visits were pro-
vided by The Norwegian Labour and Welfare Adminis-
tration (NLWA). No data for 2005 were available so
data for 2006 were used. The NLWA data encompasses
government reimbursements to hospitals. We added the
standard patient co-payment per visit (€31). According
to the financing model for hospitals, reimbursements
and co-payments encompass 40% of the estimated out-
patient clinic costs. The sum was therefore adjusted
upwards by a factor of 2.5.
Physician services
Data on the use of general practitioner (GP) services
and private specialists were obtained from NLWA.
Claim forms, 90% of which are delivered electronically
to NLWA, are provided with ICPC codes. We obtained
data on all visits with ICPC codes T89 (insulin-depen-
dent) and T90 (non-insulin-dependent) diabetes. For
each patient contact, we obtained data on diagnosis,
type of contact, reimbursement and patient co-payment.
Drugs
The Norwegian Prescription Registry (NPR) contains
information on all prescriptions redeemed from pharma-
c i e s .W eo b t a i n e dd a t af o r2 0 0 5o nt h ef o l l o w i n gc a t e -
gories of ATC codes: A10A (insulin and analogues) and
A10B (glucose lowering drugs). Additionally, we included
the costs of patient reported use of antihypertensive
drugs and cholesterol lowering drugs according to a
patient survey (see “Other types of health care”). Based
on data from the NPR we estimated average costs for one
year of treatment with antihypertensive drugs (€154) and
cholesterol lowering drugs (€357). This was based on
market share of the different drugs available, average
dose and prices.
Medical equipment
The NLWA keeps account of reimbursement for
diabetes self-tests and insulin injection equipment
(injection catheters, insulin pens and needles, syringes,
lancets for blood sampling). To avoid double counting,
the costs of insulin pumps were excluded. Insulin
pumps are administered in hospitals and costs are
captured in the DRG costing system.
Other types of health care
For various other types of resource use where register
data are not available, we obtained information through
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with diabetes (n = 1,000) was randomly drawn from the
membership file of the Norwegian Diabetes Association
(36 000 members in 2006. This file is assumed to
encompass most of the individuals in Norway with type
1 diabetes and about 15 000 with type 2 diabetes.
We developed a comprehensive questionnaire in colla-
boration with persons with diabetes and doctors with
diabetes care experience. The questionnaire was mailed
to the sample patients in May 2007. Non-responders
were followed up twice. Finally we had 584 responses
that could be used in further analyses. The respondents
were asked to state their use of the following types of
health care services considered to be relevant among
persons with diabetes for the previous three months:
physiotherapy, acupuncture, nutrition counselling and
GP home visits for hypoglycaemia. They were also asked
questions about the duration of the diabetes, type of
treatment and occurrence of diabetic related complica-
tions. To provide measures of the uncertainty of the
estimates we derived confidence intervals by applying
bootstrapping, 10 000 draws with replacement. The
questionnaire was approved by Regional Committees for
Medical Research Ethics and Norwegian Social Science
Data Services. Treatment costs were estimated by
assigning unit costs to the reported consumption of
health care services. Unit costs were taken from profes-
sional organizations (physiotherapy, acupuncture) and
GP’s fee schedule [17].
Indirect costs
Lacking data on productivity losses from diabetes, we
used payments of disability pension and economic sup-
port for diabetes related costs as a proxy for indirect
costs. Disability pension and economic support are
funded by the NLWA. We obtained data on all payments
in 2005 for the ICD-10 diagnoses: E10, E11, E23.2, H28.0,
H36.0, N08.3, O24, P70.0, P70.1, P70.2, R73.0 and Z13.1.
A search was performed with all equivalent ICD-9 codes
as well. Furthermore, the following ICPC codes were
included: T89 (insulin-dependent diabetes mellitus), T90
(non-insulin-dependent diabetes mellitus), W85 (diabetes
during pregnancy) and F83 (retinopathy).
Results
Inpatient hospital services
In 2005, there were 8 900 hospital stays with diabetes as
the main diagnosis at an estimated total cost of €21 mil-
lion (Table 1). About 65% of the costs were attributable
to insulin-dependent diabetes and 27% to non-insulin-
dependent diabetes. Additionally there were 53 000
hospital stays with diabetes as a secondary diagnosis
accounting for €242 million in costs. The most frequent
main diagnoses when diabetes was a secondary diagnosis
were cardiovascular diseases (31% of costs), malignancies
(12%) and respiratory diseases (11%). Of the secondary
diagnoses, type 2 diabetes (E11) accounted for 65%, while
type 1 (E10) accounted for 34%.
The diabetes related in-hospital costs per inhabitant
were 27% higher in the geographic region with the high-
est costs compared to region with the lowest when
accounting for admissions with diabetes as main and
secondary diagnosis. The total national in-hospital costs
would be €302 million if all regions had the same cost
level as the most costly, 15% more than the numbers
presented in Table 1.
Outpatient clinic visits
The costs related to outpatient clinic visits in hospitals
amounted to €7.9 million (included in Table 2).
Physician services
The cost of services from GPs and emergency units was
€14.4 million (Table 3) including home visits for hypo-
glycaemia. The cost relating to private practicing specia-
lists amounted to €2.5 million. On the basis of the
survey of persons with diabetes, the estimated annual
cost of physician home visits for hypoglycaemia was
€0.6 million (Table 4).
Table 1 Cost of in-hospital care according to diagnosis
Diabetes as main diagnosis Number of hospital
stays
Total
(million €)
Type 1 diabetes* 5 813 13.5
Type 2 diabetes ** 2 446 5.7
Other*** 625 1.7
Total cost - main diagnosis 8 884 20.9
Diabetes as secondary
diagnosis (ICD-10)
Number of hospital
stays
Total
(million €)
Infections (A00-A99+B00-B99) 1 686 9.3
Malignancies (C00-D89) 5 011 28.6
Neurological diseases (G00-G99) 1 401 4.2
Diseases of the eye (H00-H59) 1 405 2.3
Cardiovascular diseases (I00-I99) 14 545 74.2
Respiratory diseases (J00-J99) 4 504 25.8
Gastrointestinal diseases (K00-K93) 3 423 15.9
Musculoskeletal diseases (M00-
M99)
2 777 16.4
Urinary tract diseases (N00-N99) 3 518 16.1
Other*** 15 043 49.1
Total cost - secondary
diagnosis****
53 313 241.8
* ICD-10 code E10, Insulin-dependent diabetes mellitus
** ICD-10 code E11, Non-insulin-dependent diabetes mellitus
*** ICD-10 codes E23.2, H28, N08.3, O24, P70.0, P70.1, P70.2, R73.0, Z13.1
**** Of the secondary diagnosis type 2 diabetes (E11) accounted for 65
percent, while type 1 (E10) accounted for 34 percent.
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The cost of hypoglycaemic agents for treating diabetes
was €49.6 million (17% of total costs) (Table 5) of which
€35.1 million (70%) represented insulin and analogues
(A10A) and the rest oral glucose lowering drugs (A10B).
Within the insulin group the cost of intermediate-acting
insulin (A10AC) was €15 million and fast-acting insulin
(A10AB) was €12.5 million. In the group of glucose
lowering drugs (A10B) the cost of sulphonamides, urea
derivatives (A10BB) was €6.2 million and biguanides
(A10BA) €4.7 million. For antihypertensive drugs the
estimated cost was €1.2 and €13.0 million for type 1 and
2 diabetes, respectively, while it was €2.4 and €28.3 for
cholesterol lowering drugs.
Medical equipment
Expenditure on diabetes related medical equipment was
€40 million (Table 6). The largest component here was
glucose tests accounting for €32 million (80% of the
total). Lancets for blood sampling accounted for
approximately €5.3 million, (13% of the total).
Other types of costs
Among costs estimated on the basis of the patient sur-
vey (Table 4), physiotherapy accounted for €18.8 mil-
lion, foot therapy €20.8 million, acupuncture €5.7
million and nutrition guidance €0.9 million.
Table 2 Total cost of diabetes in Norway 2005
Cost factor Cost (million €)
Direct
costs
In hospital care 20.9
Outpatient care 7.9
GP and emergency visits 14.4
Private practicing specialist services 2.6
Insulin and analogues (A10A*) 35.1
Oral glucose lowering drugs (A10B*) 14.5
Cholesterol lowering drugs 30.7
Antihypertensive drugs 14.2
Medical devices 40.1
Nutritionist guidance 0.8
Foot therapist 19.4
Physiotherapy 16.5
Acupuncture 5.3
Subtotal (76%)
222.4
Indirect
costs
Sickness compensation 16.6
Permanent disability pension and time limited
disability pension
48.2
Basic and/or supplemental benefits 5.3
Subtotal (24%)
70.1
Total 292.5
Table 3 Cost of physician services according to type of contact
Surgery visits
(million €)
Home visits
(million €)
Other contacts
(million €)
Total cost
(million €)
GPs and emergency units
Type 1 diabetes* 0.918 0.0349 0.1633 1.117
Type 2 diabetes ** 11.646 0.1600 1.4341 13.240
Other*** 0.044 0.0001 0.0104 0.054
Subtotal 12.608 0.1952 1.6078 14.411
Specialists in private practice
Type 1 diabetes**** 0.468 0.0000 0.0122 0.480
Type 2 diabetes***** 1.616 0.0007 0.0440 1.661
Retinopathy****** 0.156 — 0.0006 0.156
Retinopathy******* 0.180 — 0.0004 0.180
Other******** 0.069 0.0012 0.070
Subtotal 2.490 0.0007 0.0582 2.549
Total 15.098 0.1959 1.6660 16.960
* ICPC code T89, Insulin-dependent diabetes
** ICPC code T90, Non-insulin-dependent diabetes
*** ICPC codes F38 Retinopathy and W85 Diabetes during pregnancy
**** ICPC code T89 and ICD-10 code E10, Insulin-dependent diabetes
***** ICPC code T90 and ICD-10 code E11, Non-insulin-dependent diabetes
****** ICPC code F83 Retinopathy
******* ICD-10 code H36.0 Retinopathy
******** E23.2, H28.0, H36.0, N08.3, O24, P70.0, P70.1, P70.2, R73.0, Z13.1
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The costs related to sick leave were €16.7 million
(Table 7) of which type 2 diabetes accounted for 85%.
Total costs related to time limited disability support and
disability pensions amounted to €48.2 million (Table 8),
of which disability pensions accounted for €46.4 million
(96%). Cost of basic and supplemental benefits was €5.3
million (Table 9).
Total costs
Total costs were €293 million (Table 2) when hospital
stays with diabetes as secondary diagnoses were
excluded and €5 3 5m i l l i o nw h e nt h e yw e r ei n c l u d e d .
The largest component was medicines with €95 million
(32% of the total). The second largest was disability pen-
sions with €48 million (16%). Medical devices contribu-
ted €40 million (14%) and hospital admissions €21
million (7%).
Discussion
The results of this study clearly indicate that diabetes
places a financial burden on the persons with diabetes
themselves and furthermore the Norwegian public
health care system. The total costs of treating diabetes
in Norway in 2005 amounted to about €293 million or
1.4% of total health care expenditures [18], or 2.6% if all
diabetes related hospital stays are included. Interestingly,
patient expenditures for acupuncture, physiotherapy and
foot therapy were many times that of those for nutri-
tional guidance. In addition, diabetes imposes costs on
society in terms of lost production from job absenteeism
and premature mortality.
Cost-of-illness analyses in general should always be
viewed in the context of potential limitations: some
costs may be underestimated, some costs may be over-
estimated and some costs are omitted. Regarding our
study, we have not accounted for productivity losses
from diabetes-related premature mortality because we
adopted the prevalence approach. In addition, diabetes
may cause complications such as cardiovascular disease,
renal failure, retinopathy, erectile dysfunction and others
that incur costs. To the extent diabetes is stated as a
secondary diagnosis at hospital discharge, such costs are
included in the €535 million estimate. With respect to
Table 4 Costs of various other services*
Resource use Unit
cost (€)
per hour/
visit
Cost
(million €)
(95% CI)**
Type 1
diabetes
Hypoglycaemia - home
visit
69 0.3 (0.1 - 0.6)
Nutritionist guidance 21 0.1 (0.1 - 0.2)
Foot therapist 53 1.4 (0.9 - 2.1)
Physiotherapy 28 2.3 (1.2 - 3.4)
Acupuncture 35 0.4 (0.1 - 0.8)
Subtotal ——— 4.5
Type 2
diabetes
Hypoglycaemia - home
visit
69 0.3 (0.0 - 0.4)
Nutritionist guidance 21 0.8 (0.5 - 1.2)
Foot therapist 53 19.4 (17.5 -
22.0)
Physiotherapy 28 16.5 (11.3 -
21.3)
Acupuncture 35 5.3 (2.6 - 10.6)
Subtotal ——— 42.3
Total 46.8
* Data collected in the patient survey
** Confidence intervals based on bootstrapping
Table 5 Cost of hypoglycaemic agents, cholesterol
lowering drugs and antihypertensive drugs
Number of
users
Million
DDD
Costs*
(million €)
Insulin and analogues (A10A**)
***
47 073 28.9 35.1
Oral glucose lowering drugs
(A10B**)***
85 014 36.2 14.5
Cholesterol lowering drugs**** 85 880 — 30.7
Antihypertensive drugs**** 92 172 — 14.2
Total —— 94.5
* Costs in terms of prices in Pharmacy sales prices including VAT
** ATC code
*** Data from the National prescription database
**** Data from a patient survey
Table 6 Cost of medical devices
Reimbursement Patient
co-payment
Total
Costs
(million €)
Glucose tests 29.484 2.096 31.580
Lancets for blood
sampling
4.885 0.378 5.262
Injection catheter 0.01 0.00024 0.010
Insulin pens 0.44 0.036 0.476
Needles for insulin pens 2.394 0,182 2.576
Insulin syringe 0.105 0.008 0.113
Urine test sticks 0.040 0.003 0.043
Total 37.358 2.703 40.061
Table 7 Cost of sick leave due to diabetes
Diagnose
(ICPC)
Number of
patients
Days of
support
Payment
(million €)
Insulin-dependent (T89) 269 17 602 1.6
Non-insulin-dependent (T90) 2 593 156 706 14.1
Retinopathy (F83) 149 7 948 0.8
Diabetes during pregnancy (W85) 38 1 523 0.13
Total 3049 183 779 16.7
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and no reliable data on the fraction attributable to
diabetes.
When estimating the cost of in-hospital care on the
basis of the main diagnosis (Table 1), some hospitals
stays may be lost even when diabetes was the main cause
of the stay. Because hospitals in Norway have partial
DRG financing, the choice of primary diagnosis may be
influenced by the financial consequences of choice of pri-
mary diagnosis. The results of a Norwegian study [19]
indicate that diabetes patients tend to have higher costs
than the average patient within certain DRGs. To the
extent that this is the case, our estimates are biased.
A lack of diabetes diagnosis may also bias costs related to
disability pensions and sick leave, physician visits, outpa-
tient clinic visits and certain other types of services
where the costing is based on diagnosis. Finally, costs
based on patient reported use of care may be underesti-
mated because patients do not recall all use of care.
When including in-hospital care for stays where diabetes
was a secondary diagnosis (Table 1), some stays may not
be caused in full by diabetes. If for example diabetes is sta-
ted as secondary diagnosis for a patient discharged from
hospital because of a malignant disease, at most a minority
of the costs may be attributable to diabetes.
Costs of hypoglycaemic agents stems from the
national prescription database and contain all prescrip-
tions redeemed in pharmacies. Costs related to drugs
provided in hospitals are included in the DRG reimbur-
sement to hospitals. Pharmaceuticals used to prevent or
treat diabetes related complications are difficult to quan-
tify, but lipid lowering and antihypertensives are
included on the basis of the patient survey.
The NLWA keeps account of reimbursement for dia-
betes related medical devices and these costs are likely
to be complete. Also, drug costs are quite accurate
because all pharmacies register prescriptions electroni-
cally and transfer their data to the central registry.
We have included some types of costs that we con-
sider relevant for persons with diabetes, such as doctor
home visits related to hypoglycaemia, nutritionist gui-
dance, foot therapy, physiotherapy and acupuncture. We
can not attribute all costs gathered in the patient survey
to diabetes. For example, there are reasons other than
diabetes for having acupuncture. It should be noted that
the survey we undertook may not be entirely representa-
tive of the diabetes population in Norway, especially for
type 2 diabetes. Some cost estimates (GP home visits for
hypoglycaemia, foot therapy, nutritional guidance, phy-
siotherapy, acupuncture, costs of cholesterol lowering-
and antihypertensive drugs) may consequently be biased,
but the impact on any bias will be small because the
relevant costs were small.
Our study provides some important general lessons
about the cost structure of diabetes care. First, the
main direct cost-drivers from diabetes are hospital
services, pharmaceuticals and medical devices. These
services are reimbursed in part or in full by govern-
ments in most industrialised countries. Second, other
types of services such as foot therapy, physiotherapy,
and acupuncture may represent considerable costs, but
often receive only partial and sometimes no reimburse-
ment by governments. In Norway, the use of foot ther-
apy is paid in full by the patient, while in contrast the
cost of foot ulcer treatment and amputations is cov-
ered almost fully by the government. This may seem
paradoxical as untreated foot ulcers may lead to infec-
tions and ultimately amputation. Finally, the study
reveals a high level of spending on acupuncture com-
pared to much lower spending on nutritional guidance.
Given the importance of diet for the progress of the
disease, this result is somewhat paradoxical and sug-
g e s t st h a tp a t i e n t sc o u l db e n e f i tf r o mad i f f e r e n t
spending pattern.
We found that hospital costs with diabetes as main
diagnosis were twice as high for type 1 diabetes as for
type 2. However, a large proportion of those with non-
insulin-dependent diabetes had CVD as the primary
diagnosis. Diabetes is likely an important causal factor
for CVD among these patients which indicates that type
2 diabetes still is a major cost driver. It is therefore
likely that type 2 diabetes is more important than type 1
diabetes with respect to hospital costs.
The number of individuals on oral glucose lowering
drugs was almost twice the number of users of insulin
and analogues. In terms of costs, the pattern was oppo-
site in that the total cost of insulin and analogues was
twice the cost of oral glucose lowering drugs. This indi-
cates that treatment of type 2 diabetes becomes more
Table 8 Cost of disability pension and time limited
disability pension related to diabetes
Benefit (€) Number of
patients
Expenditure
(million €)
Time limited disability support 17 250 112 1.9
Disability pension 16 689 2 775 46.4
Total 16 711 2 887 48.2
Table 9 Basic and supplemental benefits related to
diabetes*
Number of
patients
Expenditure
(million €)
Basic benefits 1058 1.4
Supplemental benefits 1876 3.9
Total 2934 5.3
* Approximately 15% of overall receivers of basic and supplemental benefits
are lacking diagnosis in the database
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increasingly prescribed with progression.
Our results are somewhat different from those
reported elsewhere. In Sweden the estimated costs of
hypoglycaemia related to type 2 diabetes was €14.10 per
patient per year [20] while our data would suggest about
€3 per patient. The Swedish costs are higher because of
a higher reported prevalence of hypoglycaemia and the
inclusion of indirect costs.
One should be aware of methodological differences
when comparing the results of cost-of-illness analyses.
We used a prevalence approach; studies relying on an
incidence approach with prediction of future costs may
yield higher values. Also, the method for valuing
absence from productive work may have considerable
impact on the results of cost-of-diabetes studies. Clearly,
the more types of diabetes related costs that are
included, the higher the estimated costs. A recent review
[21] suggests that there is a general tendency for indir-
ect costs to make up a slightly larger proportion of total
costs than direct costs. In the studies reviewed, the pro-
portion of indirect costs was in the range of 25-64%.
A study performed in Ireland [22] estimated that the
costs of treating diagnosed type 2 diabetes was 4.1% of
the total health care expenditure. Hospitalisations
accounted for almost half of overall costs, while ambula-
tory and medicines costs accounted for 27% and 25%.
In an early Swedish [3] study, the costs of diabetes
amounted to 5.7 billion Swedish Kroner (SEK) (€570 mil-
lion) of which 43% represented direct costs. Hospital care
estimates were based on the main diagnosis and repre-
sented the main component of direct costs. The distribu-
tion among the different types of direct costs were about
the same in the Swedish study as our. The indirect costs
in the Swedish study represented 57% of the total com-
pared to 24% in our study when including only hospital
admissions with diabetes as the main diagnosis. This dif-
f e r e n c ei si np a r ta t t r i b u t a b l et ot h ef a c tt h eS w e d i s h
study included productivity losses caused by premature
mortality while ours did not. Whether the remaining dif-
ference between the two studies is attributable to differ-
ence in time or difference in real costs is unclear.
In a recent Swedish study [23] which report increasing
costs of diabetes over time, another approach to COI
analysis is used. Diabetes prevalence and attributable
risks for diabetes complications were used to estimate
the diabetes-related costs. This approach should result
in an estimate of the COI that is between estimates
b a s e do nd i a b e t e sa st h ep r i m a r yd i a g n o s i sa n de s t i -
mates based on diabetes as the primary as well as the
secondary diagnosis.
The wide variation in methodology makes comparison
of the results difficult and calls for standardisation of
methods. Patient organisations might play a role in
developing guidelines for COI studies. Additionally,
there is a need for more research into how choice of
methods impact the results using data from the same
c o u n t r ya n dt h es a m et i m er a t h e rt h a nc o m p a r i n g
across countries. Even though COI represent a basis for
allocating research resources, most research should be
directed at studies of intervention effectiveness and how
care can be provided in the most efficient way. The lat-
ter in practice means cost-effectiveness studies, and our
COI study could be used as a toolbox for analysts in
need of cost data. If later studies are performed in the
same way, it may provide useful insight in how costs
develop over time.
Conclusions
In conclusion, the cost of diabetes represents 1.4% -
2.6% of the total health care expenditures in Norway,
depending on how diabetes related hospitalisation is
accounted for. The high diabetes costs indicate that
society may do well in devoting resources to diabetes
prevention and research.
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